CDK
Cyclin dependent kinase
CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.
There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.
CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).
CDK Isoform Specific Products
-
CDK
(478)
View all products
-
CDK1
(179)
View all products
-
CDK2
(292)
View all products
-
CDK3
(21)
View all products
-
CDK4
(221)
View all products
-
CDK5
(95)
View all products
-
CDK6
(167)
View all products
-
CDK7
(115)
View all products
-
CDK8
(54)
View all products
-
CDK9
(196)
View all products
-
CDK11
(7)
View all products
-
CDK12
(49)
View all products
-
CDK13
(25)
View all products
-
CDK14
(6)
View all products
-
CDK16
(8)
View all products
-
CDK19
(24)
View all products
-
CDC
(21)
View all products
-
CLK
(31)
View all products
-
Pho85
(1)
View all products
-
CDK10
(1)
View all products
-
CDK15
(1)
View all products
-
CDK17
(2)
View all products
-
CDK18
(1)
View all products
-
CDK20
(1)
View all products
-
PITSLRE
(1)
View all products
All Product Categories
-
CDK Inhibitors
(1043)
View all products
-
CDK Agonists
(2)
View all products
-
CDK Antagonists
(2)
View all products
-
CDK Activators
(14)
View all products
-
CDK Modulators
(14)
View all products
-
CDK Degraders
(82)
View all products
-
CDK Controls
(4)
View all products
-
CDK Substrate
(1)
View all products
-
CDK Ligands
(15)
View all products
-
Cyclin-Dependent Kinases (CDKs) Proteins
(81)
View all products
-
Cyclin Dependent Kinase 1 (CDK1) Proteins
(9)
View all products
-
Cyclin-Dependent Kinase 2 (CDK2) Proteins
(11)
View all products
-
Cyclin-Dependent Kinase 3 (CDK3) Proteins
(6)
View all products
-
Cyclin-Dependent Kinase 4 (CDK4) Proteins
(5)
View all products
-
Cyclin-Dependent Kinase 5 (CDK5) Proteins
(5)
View all products
-
Cyclin-Dependent Kinase 6 (CDK6) Proteins
(6)
View all products
-
Cyclin-Dependent Kinase 7 (CDK7) Proteins
(4)
View all products
-
CDK Related Products (1287)
Related Products (1287)
-
Recombinant Proteins (82)
-
Antibodies (42)
-
CDK Isoform Comparison
- CDK17/p35NCK Recombinant Human Active Protein Kinase
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ZDLD13
0 ImagesCat. No.: HY-115908CAS No.: 2762278-95-3ZDLD13, a β-carboline, is an orally active and selective CDK4/CycD3 inhibitor with an IC50 value of 0.38 μM. ZDLD13 exhibits potent anti-HCT116 activity including inhibition of colony formation, inhibition of invasion and migration, inducing of apoptosis, and arresting of G1 phase in cell cycle. ZDLD13 shows significant tumor growth inhibition in HCT116 tumor xenograft model. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
rel-(2S,3R)-Voruciclib hydrochloride
0 ImagesCat. No.: HY-12422ECAS No.: 1253647-46-9rel-(2S,3R)-Voruciclib hydrochloride is the rel-(2S,3R)-enantiomer of Voruciclib. Voruciclib is an orally active CDK inhibitor. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK1/2/4-IN-1
0 ImagesCat. No.: HY-146253CAS No.: 2414633-49-9CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. CDK1/2/4-IN-1 can be used for cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CIRc-014
0 ImagesCat. No.: HY-181838CAS No.: 3064485-73-7CIRc-014 is an orally active Cyclin A/B inhibitor with a Cyclin A IC50 of 0.05 μM, Cyclin A Kd of 2.7 nM, Cyclin B IC50 of less than 0.02 μM and Cyclin B Kd of 1.0 nM. CIRc-014 activates the spindle assembly checkpoint and promotes the formation of a complex between Cyclin B and CDK2 by blocking the RxL interaction of Cyclin A/B. CIRc-014 can induce replication stress, DNA damage, mitotic arrest and apoptosis in tumor cells. CIRc-014 showed tumor growth inhibition and regression in NCI-H69 and NCI-H446 small cell lung cancer xenograft models. CIRc-014 can be used for the research of small-cell lung cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Antitumor agent-174
0 ImagesCat. No.: HY-161826Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK/HDAC-IN-4
0 ImagesCat. No.: HY-169075CDK/HDAC-IN-4 is a high selective dual cyclin-dependent kinase (CDK)/histone deacetylase (HDAC) inhibitor with IC50 values of 88.4 and 168.9 nM, respectively. CDK/HDAC-IN-4 exhibits antiproliferative capacities against hematological and solid tumor cells. CDK/HDAC-IN-4 also induces MV-4-11 cell Apoptosis and S cell cycle arrests. CDK/HDAC-IN-4 possesses a significant antitumor potency in the MV-4-11 xenograft model. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK7 Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS02395 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
PRT3645
0 ImagesCat. No.: HY-153336CAS No.: 2789680-97-1PRT3645 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC50 values less than 20 nM. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CGP-74514 hydrochloride
0 ImagesCat. No.: HY-118976CAS No.: 481724-82-7Synonyms: CGP-74514ACGP-74514 hydrochloride is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC50: 25 nM). CGP-74514 hydrochloride inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G2/M phase and induces tumor cell apoptosis. CGP-74514 hydrochloride is promising for research of bladder cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
SR-2890
0 ImagesCat. No.: HY-123859CAS No.: 1454584-91-8SR-2890 is a highly selective, ATP-competitive inhibitor of casein kinase CK1δ and CK1ε, with IC50 values of 4 nM and 44 nM, respectively, and a Ki of 14 nM for CK1δ. SR-2890 exhibits antiproliferative effects. SR-2890 blocks the serine/threonine kinase activity of CK1δ and weakly inhibits a few off-target kinases such as FLT3, CDK4. SR-2890 has an oral bioavailability of 10% and a blood-brain barrier penetration rate of <1%. SR-2890 demonstrates stable in vitro metabolism and favorable in vivo pharmacokinetic properties, effectively inhibiting the growth of human A375 melanoma cells. SR-2890 can be used in melanoma research and is also a useful compound for studying CK1δ/ε-related diseases such as Alzheimer's disease. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
JD128
0 ImagesCat. No.: HY-183571CAS No.: 1934254-35-9JD128 (Compound 22) is a CDK4/6 inhibitor. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anticancer agent 299
0 ImagesCat. No.: HY-181130CAS No.: 1414873-26-9Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Cdc7-IN-8
0 ImagesCat. No.: HY-143377CAS No.: 2606780-38-3Cdc7-IN-8 is a potent inhibitor of Cdc7. Cdc7 is a serine/threonine kinase which activates MCM promotion by phosphorylating the microchromosome maintenance protein (MCM protein), an important element of the DNA replication initiator. Cdc7-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021032170A1, compound 1-1/1-2). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
GW780056X
0 ImagesCat. No.: HY-114567CAS No.: 1093294-48-4GW780056X is a CDK12 inhibitor. GW780056X decreases nuclear foci count in DM1 cells. GW780056X can be used for the research of myotonic dystrophy type 1. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK2/FLT4/PDGFRA-IN-1
0 ImagesCat. No.: HY-173124CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Cdk6 Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS02394 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK8-IN-18
0 ImagesCat. No.: HY-169541CAS No.: 642002-74-2 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK-IN-20
0 ImagesCat. No.: HY-184320CAS No.: 2776187-63-2 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anticancer agent 29
0 ImagesCat. No.: HY-115942CAS No.: 2907774-89-2Anticancer agent 29 (Compd E/Z-6f) is an anticancer agent, with IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, 0.396 μM for CDK2, CDK1, CDK4 and CDK6, respectively. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.